Loading company…
UniXell develops cell therapy drugs using human pluripotent stem cell technology.
Founded in Shanghai in 2021, UniXell Biotechnology researches cell therapies using a platform for stem cell preparation, culture, differentiation and gene editing. Its five research pipelines target neurodegenerative, rare and tumor diseases. In February 2026, it raised 50 million in Series A+ funding from Panlin Capital, Quancun Venture Capital and Waigaoqiao Private Equity Fund to advance clinical trials and development.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in